+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
MALE
ID06828263

Study to Evaluate Imaging Response Using 177LuLu-PSMA in Men with Advanced Metastatic Castration-Resistant Prostate Cancer

Led by University Hospital, Grenoble · Updated on 2025-12-26

130

Participants Needed

1

Research Sites

26 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating the use of Lutetium-177 177Lu prostate-specific membrane antigen PSMA imaging to evaluate treatment response in patients with metastatic castration-resistant prostate cancer mCRPC. This study focuses on the potential of LuPSMA-SPECTCT, a cost-effective imaging method, to serve as an early marker for assessing response to 177Lu-PSMA therapy, which has been approved for late-stage PSMA-positive mCRPC. The study aims to improve early treatment decisions and patient care by detecting tumor progression sooner. Participants will receive 177Lu-PSMA therapy and undergo serial LuPSMA-SPECTCT imaging after each treatment dose. The study will also assess interim PSMA-PETCT scans performed 10 weeks after treatment initiation. Researchers will compare the cost-effectiveness and clinical impact of SPECTCT versus PETCT imaging methods and explore additional PET imaging with 18FFDG to evaluate response. The study spans from treatment start to at least 12 months after treatment initiation. During the study, participants will have imaging scans, including LuPSMA-SPECTCT and PSMA-PETCT, to monitor tumor response and progression. Researchers will analyze tumor burden and imaging parameters to confirm the prognostic value of these imaging techniques for overall survival and progression-free survival. The study also evaluates agreement between image readers to ensure consistency. Participant involvement includes regular imaging and clinical assessments over the course of a year or longer.

CONDITIONS

Brief Title

Prospective Evaluation of Imaging Response Biomarkers During [177Lu]Lu-PSMA in Metastatic Castration-resistant Prostate Cancer

Research Team

L

Loïc DJAÏLEB, PU-PH

M

Marine FAURE

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here